Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant GS Chemotherapy vs GS plus IMRT for Resectable Pancreatic Cancer with Low CA19-9
jRCT1052240120Phase 2Recruiting
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and tegafur in pancreatic adenocarcinoma (PDAC) (2 arms). Primary endpoint: 3-year local recurrence rate. Started Oct 2024; status: recruiting.
02
Drugs
gemcitabinetegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT1052240120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1052240120.